

School of Biomedical Science**Master of Science Clinical Research
Semester End Examination - Jun 2024****Duration : 180 Minutes
Max Marks : 100****Sem II - Q1PN203T - Pharmacovigilance***General Instructions**Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- | | | |
|-----|--|--------|
| 1) | What is active surveillance? | K1(2) |
| 2) | Explain the difference between seriousness criteria and severity criteria of ADR | K2(4) |
| 3) | Explain the need and scope of post marketing surveillance | K2(6) |
| 4) | Discuss the format of PSSR. | K3(9) |
| 5) | What is Narajos' s scale. Discuss the advantage and disadvantages of Narajos's scale | K3(9) |
| 6) | Discuss the methods of Passive surveillance | K5(10) |
| 7) | What do you mean by expedited reporting. Discuss the Process of expedited reporting. | K4(12) |
| 8) | Discuss the classification of ADR based on causality. | K5(15) |
| 9) | Discuss the classification of ADR as per Upsala monitoring center. | K5(15) |
| 10) | Elaborate different methods of Pharmacovigilance. | K6(18) |